



ABN: 49 102 456 048

## **COMPANY ANNOUNCEMENT (ASX:DIA)**

### **RESULTS OF SHARE PURCHASE PLAN**

**Tuesday 23<sup>rd</sup> January 2007**

The Directors of Dia-B Tech Limited are pleased to announce that the recent Share Purchase Plan was well received by shareholders, and raised \$1,128,641.25, before costs, representing 22,572,825 new ordinary shares (DIA).

The unsubscribed shortfall from the Share Purchase Plan, originally set to raise \$1,650,000 through the issue of 33 million ordinary shares (DIA), will be placed with "excluded offerees" under Listing Rule 7.1.

Details of the placement to "excluded offerees" will be released to the market once the subscription has been finalised.

With the additional placement the Share Purchase Plan will allow the Company to accelerate the Phase 1 human clinical trial for its lead compound ISF402 which commenced in December 2006. Dosing of patients has been completed for three of the six cohorts comprising the Phase 1 trial, and progress remains on schedule.

On behalf of the Board;

Ken A Smith  
Company Secretary  
Dia-B Tech Limited